GlassScriptPhysician profile
Leah Bowers
NPI 1114983665
$7,650.46
in general payments reported to CMS, 2019-2025
33 companies · $2,996 in 2025
The $2,996 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $251 · 2023: $1,759 · 2024: $2,645 · 2025: $2,996.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,399.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,399.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,426.65 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $1,072.27 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $915.94 | 2022-2025 | Breztri, Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $601.34 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $537.29 | 2023-2025 | |
| Novo Nordisk INC | $389.57 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Dexcom, INC. | $335.69 | 2022-2025 | Dexcom G6 Transmitter |
| Ardelyx, INC. | $317.15 | 2024-2025 | Ibsrela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $304.80 | 2023-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $258.31 | 2023-2025 | |
| Shield Therapeutics INC | $177.60 | 2023-2025 | Accrufer |
| Kowa Pharmaceuticals America, INC. | $171.76 | 2023-2025 | Zoryve, Livalo |
| Abbott Laboratories | $163.13 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $154.99 | 2023-2025 | Xifaxan, Trulance |
| Ironwood Pharmaceuticals, INC | $146.47 | 2023-2024 | Linzess |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $91.68 | 2025 | Gemtesa |
| Merck Sharp & Dohme LLC | $69.97 | 2023-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Vanda Pharmaceuticals INC. | $68.17 | 2025 | Fanapt |
| Axsome Therapeutics, INC. | $59.10 | 2025 | Auvelity |
| Inspire Medical Systems, INC. | $42.27 | 2023-2025 | Inspire |
| Lundbeck LLC | $41.11 | 2025 | Rexulti |
| Xeris Pharmaceuticals, INC. | $40.15 | 2023 | Gvoke Hypopen |
| Astellas Pharma US INC | $37.72 | 2025 | Veozah |
| Exact Sciences Corporation | $34.62 | 2024 | Cologuard Collection Kit |
| Amgen INC. | $31.13 | 2023 | Prolia, Evenity |
| Abiomed | $26.63 | 2024 | Impella |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.72 | 2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $21.50 | 2023 | Trintellix |
| Sanofi-Aventis U.S. LLC | $20.63 | 2023 | |
| Biogen, INC. | $19.53 | 2024 | Skyclarys |
| Novartis Pharmaceuticals Corporation | $17.69 | 2022 | |
| Genzyme Corporation | $17.20 | 2025 | |
| Phathom Pharmaceuticals, INC. | $16.68 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leah Bowers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.